Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Revenue (2021 - 2024)

Allogene Therapeutics' Revenue history spans 4 years, with the latest figure at $22000.0 for Q1 2024.

  • For Q1 2024, Revenue fell 26.67% year-over-year to $22000.0; the TTM value through Dec 2024 reached $22000.0, down 81.03%, while the annual FY2024 figure was $22000.0, 76.84% down from the prior year.
  • Revenue for Q1 2024 was $22000.0 at Allogene Therapeutics, up from $21000.0 in the prior quarter.
  • Across five years, Revenue topped out at $75.7 million in Q4 2021 and bottomed at $4000.0 in Q4 2022.
  • The 4-year median for Revenue is $39000.0 (2022), against an average of $8.8 million.
  • The largest annual shift saw Revenue plummeted 99.99% in 2022 before it soared 425.0% in 2023.
  • A 4-year view of Revenue shows it stood at $75.7 million in 2021, then tumbled by 99.99% to $4000.0 in 2022, then skyrocketed by 425.0% to $21000.0 in 2023, then increased by 4.76% to $22000.0 in 2024.
  • Per Business Quant, the three most recent readings for ALLO's Revenue are $22000.0 (Q1 2024), $21000.0 (Q4 2023), and $43000.0 (Q3 2023).